Epidemiology and Clinical Features of Bloodstream Infections in Hematology Wards: One Year Experience at the Catholic Blood and Marrow Transplantation Center
1
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Background: The aim of this study was to investigate the clinical features and epidemiology of bloodstream infections (BSIs)in 2 distinctive hematological wards of the Catholic Blood and Marrow Transplantation (BMT) center. Materials and Methods: We retrospectively reviewed the medical data of patients who developed BSIs from June 2009 to May 2010 in 2 hematologic wards at the Catholic BMT center. Ward A is a 44-bed unit mainly conducting conventional high dose chemotherapy and ward B is a 23-bed unit exclusively conducting BMT. Results: Overall, 222 BSI episodes were developed from 159 patients. Acute myeloid leukemia in ward A and multiple myeloma in ward B were more frequent than in ward B and A, respectively. Sex, age, presence of neutropenia, shock, Pitt bacteremia score, type of central catheter, level of C-reactive protein, duration of admission days, type of BSI, overall mortality and distribution of organisms were not different between the 2 wards. There were 202 monomicrobial and 20 polymicrobial BSI episodes, including 2 fungemia episodes. The incidence rate of overall BSIs per 1,000 patient-days was higher in ward A than in ward B (incidence rate ratio 2.88, 95% confidence interval 1.97-4.22, P<0.001). Among 243 organisms isolated, the number of gram positives, gram negatives and fungi were 122, 119 and 2, respectively. Escherichia coli was the most common organism in both ward A and B (27.6% and 42.4%), followed by viridians streptococci (18.6% and 15.2%)and Klebsiella pneumoniae (13.3% and 9.0%). Extended spectrum beta-lactamase (ESBL) producers accounted for 31.9%(23/72) of E. coli and 71.0% (22/31) of K. pneumoniae. Out of 19 Enterococcus faecium, 7 isolates (36.8%) were resistant to vancomycin. The crude mortality rates at 7 and 30 days after each BSI episode were 4.5% (10/222) and 13.1% (29/222), and were significantly higher in the patients with shock compared with those without shock (20.5% vs. 1.1%, P<0.001 and 38.5% vs. 7.7%, P<0.001, respectively). Conclusions: The incidence rate of BSIs was higher in patients receiving chemotherapy than those receiving BMT, but the distribution of organisms was not different between the 2 wards. E. coli was the most common causative BSI organism in hematologic wards followed by viridians streptococci and K. pneumoniae.
Abstract
Background: The aim of this study was to investigate the clinical features and epidemiology of bloodstream infections (BSIs)in 2 distinctive hematological wards of the Catholic Blood and Marrow Transplantation (BMT) center. Materials and Methods: We retrospectively reviewed the medical data of patients who developed BSIs from June 2009 to May 2010 in 2 hematologic wards at the Catholic BMT center. Ward A is a 44-bed unit mainly conducting conventional high dose chemotherapy and ward B is a 23-bed unit exclusively conducting BMT. Results: Overall, 222 BSI episodes were developed from 159 patients. Acute myeloid leukemia in ward A and multiple myeloma in ward B were more frequent than in ward B and A, respectively. Sex, age, presence of neutropenia, shock, Pitt bacteremia score, type of central catheter, level of C-reactive protein, duration of admission days, type of BSI, overall mortality and distribution of organisms were not different between the 2 wards. There were 202 monomicrobial and 20 polymicrobial BSI episodes, including 2 fungemia episodes. The incidence rate of overall BSIs per 1,000 patient-days was higher in ward A than in ward B (incidence rate ratio 2.88, 95% confidence interval 1.97-4.22, P<0.001). Among 243 organisms isolated, the number of gram positives, gram negatives and fungi were 122, 119 and 2, respectively. Escherichia coli was the most common organism in both ward A and B (27.6% and 42.4%), followed by viridians streptococci (18.6% and 15.2%)and Klebsiella pneumoniae (13.3% and 9.0%). Extended spectrum beta-lactamase (ESBL) producers accounted for 31.9%(23/72) of E. coli and 71.0% (22/31) of K. pneumoniae. Out of 19 Enterococcus faecium, 7 isolates (36.8%) were resistant to vancomycin. The crude mortality rates at 7 and 30 days after each BSI episode were 4.5% (10/222) and 13.1% (29/222), and were significantly higher in the patients with shock compared with those without shock (20.5% vs. 1.1%, P<0.001 and 38.5% vs. 7.7%, P<0.001, respectively). Conclusions: The incidence rate of BSIs was higher in patients receiving chemotherapy than those receiving BMT, but the distribution of organisms was not different between the 2 wards. E. coli was the most common causative BSI organism in hematologic wards followed by viridians streptococci and K. pneumoniae.
참고문헌 (34)
- Cherif H, "Bacteraemiain hospitalised patients with malignant blood disorders: aretrospective study of causative agents and their resistanceprofiles during a 14-year period without antibacterial prophylaxis", Hematol J, 4, pp.420~426 (2003)
- Worth LJ, "Bloodstream infections in haematology:risks and new challenges for prevention", Blood Rev, 23, pp.113~122 (2009)
- Ramphal R, "Changes in the etiology of bacteremia in febrileneutropenic patients and the susceptibilities of the currentlyisolated pathogens", Clin Infect Dis, 39(1), pp.S25~S31 (2004)
- Wisplinghoff H, "Currenttrends in the epidemiology of nosocomial bloodstreaminfections in patients with hematological malignancies andsolid neoplasms in hospitals in the United States", Clin InfectDis, 36, pp.1103~1110 (2003)
- Jugo J, "Trends in bacteraemiaon the haematology and oncology units of a UK tertiary referralhospital", J Hosp Infect, 50, pp.48~55 (2002)
- Chen CY, "Epidemiology of bloodstream infections in patientswith haematological malignancies with and withoutneutropenia", Epidemiol Infect, 138, pp.1044~1051 (2010)
- 이동건, "Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea", The Korean Journal of Internal Medicine, 26(2), pp.220~252 (2011), 대한내과학회
- Zinner SH, "Changing epidemiology of infections in patientswith neutropenia and cancer: emphasis on gram-positiveand resistant bacteria", Clin Infect Dis, 29, pp.490~494 (1999)
- Mikulska M, "Blood stream infections in allogeneic hematopoietic stemcell transplant recipients: reemergence of Gram-negativerods and increasing antibiotic resistance", Biol Blood MarrowTransplant, 15, pp.47~53 (2009)
- Wang FD, "Bacteremia in patients with hematologicalmalignancies", Chemotherapy, 51, pp.147~153 (2005)
- Oliveira AL, "Epidemiologyof bacteremia and factors associated with multidrug-resistant gram-negative bacteremia in hematopoieticstem cell transplant recipients", Bone Marrow Transplant, 39, pp.775~781 (2007)
- Sun Hee Park, "Current Trends of Infectious Complications following Hematopoietic Stem Cell Transplantation in a Single Center", Journal of Korean Medical Science, 21(2), pp.199~207 (2006), 대한의학회
- 최수미, "급성 백혈병 환자의 감염양상 : 관해 유도 및 재관해유도 화학요법 환자군의 비교", Infection and Chemotherapy, 35(2), pp.78~85 (2003), 대한감염학회
- Choi H, "The spectrum of infection inpatients with acute leukemia", Korean J Med, 46, pp.496~504 (1994)
- Gonzalez-Barca E, "Prognostic factors influencingmortality in cancer patients with neutropenia and bacteremia", Eur J Clin Microbiol Infect Dis, 18, pp.539~544 (1999)
- Rokusz L, "Infections of febrile neutropenic patientsin malignant hematological diseases", Mil Med, 168, pp.355~359 (2003)
- Escande MC, "Prospective study of bacteraemiain cancer patients. Results of a French multicentrestudy", Support Care Cancer, 6, pp.273~280 (1998)
- Elting LS, "Outcomesof bacteremia in patients with cancer and neutropenia: observationsfrom two decades of epidemiological and clinicaltrials", Clin Infect Dis, 25, pp.247~259 (1997)
- Paul M, "Beta lactam monotherapyversus beta lactam-aminoglycoside combinationtherapy for fever with neutropenia: systematic review andmeta-analysis", BMJ, 326, pp.1111~ (2003)
- Wang FD, "Bacteremia in patients with hematologicmalignancies", J Formos Med Assoc, 97, pp.405~409 (1998)
- Wang FD, "A comparative study of cefepime versus ceftazidime asempiric therapy of febrile episodes in neutropenic patients", Chemotherapy, 45, pp.370~379 (1999)
- Baskaran ND, "Bacteremia inpatients with febrile neutropenia after chemotherapy ata university medical center in Malaysia", Int J Infect Dis, 11, pp.513~517 (2007)
- Gupta N, "CarbapenemresistantEnterobacteriaceae: epidemiology and prevention", Clin Infect Dis, 53, pp.60~67 (2011)
- Hu F, "Emergenceof carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China", J MedMicrobiol, 61, pp.132~136 (2012)
- Zarfel G, "Emergence of carbapenemresistantEnterobacteriaceae in Austria 2001-2010", ClinMicrobiol Infect, 17, pp.E5~E8 (2011)
- Hoecker JL, "Streptococcussalivarius sepsis in children with malignancies", J Pediatr, 92, pp.337~338 (1978)
- Pizzo PA, "Alpha-hemolytic streptococci:clinical significance in the cancer patient", Med PediatrOncol, 4, pp.367~370 (1978)
- Shenep JL, "Viridans-group streptococcal infections inimmunocompromised hosts", Int J Antimicrob Agents, 14, pp.129~135 (2000)
- Tunkel AR, "Infections caused by viridansstreptococci in patients with neutropenia", Clin Infect Dis, 34, pp.1524~1529 (2002)
- Almyroudis NG, "Pre- andpost-engraftment bloodstream infection rates and associatedmortality in allogeneic hematopoietic stem cell transplantrecipients", Transpl Infect Dis, 7, pp.11~17 (2005)
- Todeschini G, "Associationbetween Enterococcus bacteraemia and death in neutropenicpatients with haematological malignancies", J Infect, 53, pp.266~273 (2006)
- Freifeld AG, "InfectiousDiseases Society of America. Clinical practice guideline forthe use of antimicrobial agents in neutropenic patients withcancer: 2010 update by the infectious diseases society ofamerica", Clin Infect Dis, 52, pp.e56~e93 (2011)
- Sancho S, "Impact of nosocomial polymicrobial bloodstreaminfections on the outcome in critically ill patients", Eur J Clin Microbiol Infect Dis, 31, pp.1791~1796 (2012)
- Reuben AG, "Musher DM, Hamill RJ, Broucke I. Polymicrobialbacteremia: clinical and microbiologic patterns", RevInfect Dis, 11, pp.161~183 (1989)